Serostatus following live attenuated vaccination administered before pediatric liver transplantation
| Autor: | Akihiko Saitoh, Kensuke Shoji, Isao Miyairi, Ippei Miyata, Mureo Kasahara, Hironori Yoshii, Seisuke Sakamoto, Takanori Funaki |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
medicine.medical_specialty Adolescent medicine.medical_treatment Liver transplantation Measles Rubella Chickenpox Vaccine Young Adult Biliary atresia Internal medicine Living Donors medicine Humans Child Adverse effect Immunosuppression Therapy Transplantation Hepatology business.industry Infant Immunosuppression medicine.disease Liver Transplantation Vaccination Child Preschool Immunology Female Surgery Serostatus business Measles-Mumps-Rubella Vaccine |
| Zdroj: | Liver Transplantation. 21:774-783 |
| ISSN: | 1527-6473 1527-6465 |
| Popis: | After liver transplantation (LT), live attenuated vaccines (LAVs) are generally contraindicated. LAVs are recommended before LT for patients ≥ 6 months of age. However, the evidence supporting this practice is limited. Patients were enrolled before and after LT. Clinical data for patients were obtained from medical records. Serum antibody titers were evaluated at the time of enrollment and prospectively. Serum antibody titers were measured with a hemagglutination inhibition test for measles and rubella and with an enzyme-linked immunosorbent assay for varicella and mumps. Univariate and multivariate analyses were performed to investigate the factors that affect the serostatus. Serological analyses of 49 patients immunized before LT (median age, 45 months; male, 35%) were performed. Underlying diseases were biliary atresia (n = 27; 55%), metabolic diseases (n = 13; 27%), fulminant hepatic failure (n = 5; 10%), and others (n = 4; 8%). The seropositivity rate after each vaccine was 46.9% (measles), 89.4% (rubella), 67.5% (varicella), and 48.8% (mumps). Factors independently associated with seronegativity were a vaccination age |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text